Scarica l'app Stockscreener
0.72
1.23%
-0.009
Dopo l'orario di chiusura:
.74
0.02
+2.78%
Precedente Chiudi:
$0.729
Aprire:
$0.749
Volume 24 ore:
20,575
Relative Volume:
0.59
Capitalizzazione di mercato:
$28.92M
Reddito:
-
Utile/perdita netta:
$-24.77M
Rapporto P/E:
-0.9351
EPS:
-0.77
Flusso di cassa netto:
$-17.36M
1 W Prestazione:
-1.37%
1M Prestazione:
+0.40%
6M Prestazione:
-26.53%
1 anno Prestazione:
-38.46%
Intervallo 1D:
$0.72
$0.749
Intervallo di 1 settimana:
$0.6765
$0.75
Portata 52W:
$0.57
$1.90
Mink Therapeutics Inc Stock (INKT) Company Profile
Nome
Mink Therapeutics Inc
Settore
Industria
Telefono
212-994-8250
Indirizzo
149 FIFTH AVENUE, NEW YORK
Mink Therapeutics Inc Borsa (INKT) Ultime notizie
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board - TipRanks
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 - The Manila Times
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors - GlobeNewswire
Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
BBerg Commodity Index (AHH20) Quote - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Altria Group (MO-N) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
TSX Global Base Metals Index (TXBM) QuotePress Release - The Globe and Mail
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Alphabet Cl C (GOOG-Q) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, - openPR
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
CAR-T Cell Therapy Competitive Landscape 2024 (Updated) - openPR
MiNK Therapeutics announces executive transition By Investing.com - Investing.com Australia
MiNK Therapeutics announces executive transition - Investing.com India
Renaissance Technologies LLC Invests $117,000 in Generation Income Properties, Inc. (NASDAQ:GIPR) - Defense World
Rx Rundown: AstraZeneca, Danco Laboratories, GSK and more - MM+M Online
Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
MiNK Therapeutics stock gets boost from new RNA collaboration with Autonomous - Investing.com Canada
Mink Therapeutics and Autonomous Therapeutics target metastatic tumors through new collaboration - BioWorld Online
Investor’s Toolkit: Key Ratios for Assessing MiNK Therapeutics Inc (INKT)’s Performance - The Dwinnex
MiNK Therapeutics, Autonomous Therapeutics enter research collaboration - TipRanks
ZenaTech's ZenaDrone Commences Aerial Operations to Commercialize Drone Services in the US Following FAA Approval - The Manila Times
MiNK Therapeutics and Autonomous Therapeutics Announce - GlobeNewswire
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors - Yahoo Finance
Mink Therapeutics stock hits 52-week low at $0.71 amid market challenges - Investing.com
Mink Therapeutics stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - The Manila Times
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 - The Bakersfield Californian
Voyageur Mineral Explorers Corp. Options Mink Narrows Project - Yahoo Finance
Oatly Group (NASDAQ:OTLY) Trading Down 4.9% - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Position Boosted by Northeast Financial Consultants Inc - Defense World
KeyCorp Raises Xcel Energy (NASDAQ:XEL) Price Target to $69.00 - Defense World
BlackRock Short Duration Bond ETF (BATS:NEAR) Sets New 52-Week High at $51.31 - Defense World
Creative Planning Purchases 14,858 Shares of Novartis AG (NYSE:NVS) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Twin Lakes Capital Management LLC Sells 125 Shares of The Boeing Company (NYSE:BA) - Defense World
Invst LLC Raises Stock Holdings in Phillips 66 (NYSE:PSX) - Defense World
Mink Therapeutics Inc Azioni (INKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):